Literature DB >> 1469086

O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b.

J A Carew1, S M Quinn, J H Stoddart, D C Lynch.   

Abstract

By transfecting the full-length cDNA for human von Willebrand factor (vWf) into a line of Chinese hamster ovary cells with a defect in carbohydrate metabolism, we have prepared recombinant vWf specifically lacking O-linked carbohydrates. We have compared this under-glycosylated protein to fully glycosylated recombinant vWf with respect to several structural and binding properties. vWf deficient in O-linked glycans was synthesized, assembled into multimers, and secreted in an apparently normal manner and was not prone to degradation in the extracellular milieu. It did not differ from fully glycosylated vWf in ability to bind to heparin or to collagen type I but did interact less well with glycoprotein 1b on formalin-fixed platelets. This decreased interaction was evidenced in both a lessened overall binding to platelets and in diminished capacity to promote platelet agglutination, in the presence of ristocetin. In contrast, no difference was seen in platelet binding in the presence of botrocetin. These data indicate a possible role for O-linked carbohydrates in the vWf-glycoprotein 1b interaction promoted by ristocetin and suggest that abnormalities in carbohydrate modification might contribute to the altered ristocetin-dependent reactivity between vWf and platelets described for some variant forms of von Willebrand disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469086      PMCID: PMC443377          DOI: 10.1172/JCI116112

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  55 in total

1.  Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease.

Authors:  C S Jenkins; D R Phillips; K J Clemetson; D Meyer; M J Larrieu; E F Lüscher
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

2.  Sulfation of von Willebrand factor.

Authors:  J A Carew; P J Browning; D C Lynch
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  Isolation and chemical characterization of two structurally and functionally distinct forms of botrocetin, the platelet coagglutinin isolated from the venom of Bothrops jararaca.

Authors:  Y Fujimura; K Titani; Y Usami; M Suzuki; R Oyama; T Matsui; H Fukui; M Sugimoto; Z M Ruggeri
Journal:  Biochemistry       Date:  1991-02-19       Impact factor: 3.162

4.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

5.  Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.

Authors:  Z M Ruggeri; F I Pareti; P M Mannucci; N Ciavarella; T S Zimmerman
Journal:  N Engl J Med       Date:  1980-05-08       Impact factor: 91.245

6.  O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity.

Authors:  M Oh-eda; M Hasegawa; K Hattori; H Kuboniwa; T Kojima; T Orita; K Tomonou; T Yamazaki; N Ochi
Journal:  J Biol Chem       Date:  1990-07-15       Impact factor: 5.157

7.  Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets.

Authors:  J P Scott; R R Montgomery; G S Retzinger
Journal:  J Biol Chem       Date:  1991-05-05       Impact factor: 5.157

8.  Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.

Authors:  S E Lyons; M E Bruck; E J Bowie; D Ginsburg
Journal:  J Biol Chem       Date:  1992-03-05       Impact factor: 5.157

9.  Studies on anti-von Willebrand factor (vWF) monoclonal antibody NMC-4, which inhibits both ristocetin- and botrocetin-induced vWF binding to platelet glycoprotein Ib.

Authors:  Y Fujimura; Y Usami; K Titani; K Niinomi; K Nishio; T Takase; A Yoshioka; H Fukui
Journal:  Blood       Date:  1991-01-01       Impact factor: 22.113

10.  Structure determination of the major asparagine-linked sugar chain of human factor VIII--von Willebrand factor.

Authors:  P Debeire; J Montreuil; B Samor; C Mazurier; M Goudemand; H van Halbeek; J F Vliegenthart
Journal:  FEBS Lett       Date:  1983-01-10       Impact factor: 4.124

View more
  12 in total

1.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.

Authors:  Sandra L Haberichter; Michael Balistreri; Pamela Christopherson; Patricia Morateck; Stefana Gavazova; Daniel B Bellissimo; Marilyn J Manco-Johnson; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

Review 2.  von Willebrand factor, Jedi knight of the bloodstream.

Authors:  Timothy A Springer
Journal:  Blood       Date:  2014-06-13       Impact factor: 22.113

3.  Patterns and levels of platelet glycosylation in patients with coronary heart disease and type 2 diabetes mellitus.

Authors:  Liping Li; Chenxue Qu; Xuelian Wu; Juhua Dai; Yao Lu; Yan Gong; Ran You; Yaqi Liu
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

4.  Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.

Authors:  Sandra L Haberichter; Elizabeth P Merricks; Scot A Fahs; Pamela A Christopherson; Timothy C Nichols; Robert R Montgomery
Journal:  Blood       Date:  2004-08-26       Impact factor: 22.113

5.  Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbα.

Authors:  Caroline Kardeby; Knut Fälker; Elizabeth J Haining; Maarten Criel; Madelene Lindkvist; Ruben Barroso; Peter Påhlsson; Liza U Ljungberg; Mattias Tengdelius; G Ed Rainger; Stephanie Watson; Johannes A Eble; Marc F Hoylaerts; Jonas Emsley; Peter Konradsson; Steve P Watson; Yi Sun; Magnus Grenegård
Journal:  Blood Adv       Date:  2019-02-12

6.  Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands.

Authors:  Lesley G Ellies; David Ditto; Gallia G Levy; Mark Wahrenbrock; David Ginsburg; Ajit Varki; Dzung T Le; Jamey D Marth
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-03       Impact factor: 11.205

7.  Platelet biogenesis and functions require correct protein O-glycosylation.

Authors:  Yingchun Wang; Shawn M Jobe; Xiaokun Ding; Hyojung Choo; David R Archer; Rongjuan Mi; Tongzhong Ju; Richard D Cummings
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

8.  Promotion of binding of von Willebrand factor to platelet glycoprotein Ib by dimers of ristocetin.

Authors:  M F Hoylaerts; K Nuyts; K Peerlinck; H Deckmyn; J Vermylen
Journal:  Biochem J       Date:  1995-03-01       Impact factor: 3.857

Review 9.  Recombinant von Willebrand factor: potential therapeutic use.

Authors:  B E Fischer
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 5.221

10.  In vivo analysis of the role of O-glycosylations of von Willebrand factor.

Authors:  Idinath Badirou; Mohamad Kurdi; Paulette Legendre; Julie Rayes; Marijke Bryckaert; Caterina Casari; Peter J Lenting; Olivier D Christophe; Cecile V Denis
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.